- Home
- PAII vs CATX Comparison
PAII vs CATX Comparison
Compare PAII & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$0.85
Company Overview
Basic Information| Metric | PAII | CATX |
|---|---|---|
| Founded | 2025 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.4M | 262.5M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PAII | CATX |
|---|---|---|
| Price | $10.34 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $10.57 |
| AVG Volume (30 Days) | 224.6K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.02 | $0.84 |
| 52 Week High | $10.36 | $6.16 |
Technical Indicators
Market Signals| Indicator | PAII | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 67.84 | 20.68 |
| Support Level | $10.27 | N/A |
| Resistance Level | $10.36 | $2.40 |
| Average True Range (ATR) | 0.01 | 0.21 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 100.00 | 4.72 |
Price Performance
Historical Comparison PAII
CATX
About PAII Pyrophyte Acquisition Corp. II Class A Ordinary Shares
Pyrophyte Acquisition Corp II is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.